Oral mucositis (moderate to severe) · Patients with cancer receiving radiotherapy, chemotherapy or targeted therapies
Keratinocyte GF 50 mg showed no clear difference in oral mucositis (moderate to severe) compared with keratinocyte GF 25 mg; GRADE not reported.
1 finding from 1 review
Oral mucositis (severe) · Patients with cancer receiving radiotherapy, chemotherapy or targeted therapies
Keratinocyte GF 50 mg showed no clear difference in oral mucositis (severe) compared with keratinocyte GF 25 mg; GRADE not reported.
1 finding from 1 review
Maximal mouth opening (interincisal distance) · People of any age with a confirmed diagnosis, by clinical examination and biopsy, of oral submucous fibrosis (OSF)
It is very uncertain whether intralesional triamcinolone changes maximal mouth opening (interincisal distance) compared with intralesional triamcinolone plus salvianolic acid B (very low certainty).
1 finding from 1 review
Burning sensation (VAS 0-100) · People of any age with a confirmed diagnosis, by clinical examination and biopsy, of oral submucous fibrosis (OSF)
It is very uncertain whether intralesional triamcinolone changes burning sensation (VAS 0-100) compared with intralesional triamcinolone plus salvianolic acid B (very low certainty).
2 findings from 1 review
MD -1.00 [-10.37, 8.37]
1 study · 28 participants
Very low
MD -16.30 [-28.15, -4.45]
1 study · 28 participants
Very low
Oral mucositis (any severity) · Adults with cancer receiving treatment
1 finding from 1 review
Pain (mean score) · People with symptomatic, biopsy-confirmed oral lichen planus (OLP); not concurrently receiving other OLP treatment
1 finding from 1 review
Clinical score · People with symptomatic, biopsy-confirmed oral lichen planus (OLP); not concurrently receiving other OLP treatment
1 finding from 1 review
Adverse events · Adolescents and adults aged over 16 years with clinical or self-assessed halitosis of oral origin; excluding induced or physiological…
The review found no eligible studies for this question.
1 finding from 1 review
VSC: methyl mercaptan · Adolescents and adults aged over 16 years with clinical or self-assessed halitosis of oral origin; excluding induced or physiological…
Hinokitiol gel showed no clear difference in VSC: methyl mercaptan compared with placebo gel; GRADE not reported.
1 finding from 1 review
Dentist-reported organoleptic test (OLT) score (scale 0 to 5) · Adolescents and adults aged over 16 years with clinical or self-assessed halitosis of oral origin; excluding induced or physiological…
It is very uncertain whether hinokitiol gel changes dentist-reported organoleptic test (OLT) score (scale 0 to 5) compared with placebo gel (very low certainty).
1 finding from 1 review
Patient-reported OLT score · Adolescents and adults aged over 16 years with clinical or self-assessed halitosis of oral origin; excluding induced or physiological…
The review found no eligible studies for this question.
1 finding from 1 review
VSC: hydrogen sulphide · Adolescents and adults aged over 16 years with clinical or self-assessed halitosis of oral origin; excluding induced or physiological…
Hinokitiol gel showed no clear difference in VSC: hydrogen sulphide compared with placebo gel; GRADE not reported.
1 finding from 1 review
Oral mucositis (moderate to severe) · Patients with cancer receiving radiotherapy, chemotherapy or targeted therapies
Keratinocyte GF led to lower oral mucositis (moderate to severe) compared with placebo; GRADE not reported.
1 finding from 1 review
RR 0.74 [0.62, 0.89]
7 studies
GRADE not reported
Oral mucositis (severe) · Patients with cancer receiving radiotherapy, chemotherapy or targeted therapies
Keratinocyte GF may leads to lower oral mucositis (severe) compared with placebo (low certainty).
1 finding from 1 review
Oral mucositis (any severity) · Patients with cancer receiving radiotherapy, chemotherapy or targeted therapies
Keratinocyte GF may leads to lower oral mucositis (any severity) compared with placebo (low certainty).
1 finding from 1 review
Improvement in mucositis · People with cancer receiving chemotherapy or radiotherapy (or both) who have oral mucositis
Allopurinol mouthwash led to higher improvement in mucositis compared with placebo; GRADE not reported.
1 finding from 1 review
Mucositis eradicated · People with cancer receiving chemotherapy or radiotherapy (or both) who have oral mucositis
Allopurinol mouthwash led to higher mucositis eradicated compared with placebo; GRADE not reported.
1 finding from 1 review
Time to heal mucositis (days) · People with cancer receiving chemotherapy or radiotherapy (or both) who have oral mucositis
Allopurinol mouthwash led to lower time to heal mucositis (days) compared with placebo; GRADE not reported.
1 finding from 1 review
Oral mucositis (moderate to severe) · Patients with cancer receiving radiotherapy, chemotherapy or targeted therapies
Allopurinol mouthrinse led to lower oral mucositis (moderate to severe) compared with placebo/no treatment; GRADE not reported.
1 finding from 1 review
RR 0.66 [0.5, 0.86]
2 studies
GRADE not reported
Oral mucositis (any severity) · Patients with cancer receiving radiotherapy, chemotherapy or targeted therapies
Allopurinol mouthrinse showed no clear difference in oral mucositis (any severity) compared with placebo/no treatment; GRADE not reported.
1 finding from 1 review
RR 0.77 [0.5, 1.19]
4 studies
GRADE not reported